Clinical trials on the efficacy and safety of Shikuwasa seed extract extracted from Shikuwasa seed for motor function

Clinical trials on the efficacy and safety of Shikuwasa seed extract for motor function - Clinical trials on the efficacy and safety of Shikuwasa seed extract for motor function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048625

Enrollment

Registered

2022-08-08

Start date

2022-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decline in motor function with aging

Interventions

The test product is No. 2 hard capsule (made of hydroxypropyl methylcellulose) containing 160 mg of Shikuwasa seed extract (containing 65% nomilin and 25% limonin). The 50 subjects will be divided in

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women over the age of 65 who are basically healthy but feel some decline in motor function with age.

Exclusion criteria

Exclusion criteria: 1.Those who are being treated for motor dysfunction or taking supplements thereof 2.Those within half a year after the end of treatment for motor dysfunction 3.Those with disabilities in the limbs 4.Those who need long-term care to stand up or walk 5.Things that are difficult to communicate 6.Others that the attending physician deems inappropriate for registration in this study

Design outcomes

Primary

Measure	Time frame
6-minute walking test	—

Secondary

Measure	Time frame
BMI, body fat percentage, grip strength measurement, chair standing test, HbA1c	—

Countries

Japan

Contacts

Public ContactKimio Sugaya

Southern Knights' Laboratory Co., Ltd. CEO

sugaya@sklabo.co.jp09049987459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026